Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals and sickening people.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.